An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia

Table 2 Percentages of cancer stem cells

Stem cell %	Cell line	Conditions	Reference
20%	SUM147	control	[83]
10%	SUM147	treatment	[83]
1–15%	MDA-MB-231		[84]
1%	MDA-MB-231	ALDH1	[85]
12%	MDA-MB-231	Paclitaxel	"
1–13%	SUM159	with/− Paclitaxel	"
6–24%	SUM149	"	[86]
8–34%	SUM159	"	"
0.2%–12%	tumors	ALDH1	[87]
3.10%	MDA-MB-231		[88]
2.70%	MDA-MB-435		"
~0.5%	SUM225	CD44⁺/CD24⁻/ESA⁺	[89]
~2.5%	SUM149	CD44⁺/CD24⁻/ESA⁺	"
~1.75%	SUM159	CD44⁺/CD24⁻/ESA⁺	"
~2.5%	SUM1315	CD44⁺/CD24⁻/ESA⁺	"
~2%	MDA-MB-231	CD44⁺/CD24⁻/ESA⁺	"
9–20%	MDA-MB-231	CD44⁺/CD24	Our data

ISSN: 1752-0509